10-K: Inovio Pharmaceuticals Faces Going Concern Doubt Amid FDA Scrutiny

Inovio Pharmaceuticals reports a $84.9 million net loss for 2025 and faces substantial doubt about its ability to continue as a going concern, while its lead RRP candidate, INO-3107, encounters FDA questions on accelerated approval eligibility.

Summary

• Inovio Pharmaceuticals reported a net loss of $84.9 million for the year ended December 31, 2025, an improvement from a $107.3 million net loss in 2024.
• Revenue from collaborative arrangements significantly decreased to $65,343 in 2025 from $217,756 in 2024, with all revenue derived from ApolloBio Corporation.
• Research and development expenses decreased by 28% to $54.2 million in 2025 from $75.6 million in 2024, primarily due to lower drug manufacturing, clinical study, and contract labor costs.
• General and administrative expenses decreased by 12% to $32.7 million in 2025 from $37.0 million in 2024.
• Cash, cash equivalents, and short-term investments totaled $58.5 million as of December 31, 2025, down from $94.1 million in 2024.
• The company's accumulated deficit reached $1.8 billion as of December 31, 2025.
• Management believes there is substantial doubt about the company's ability to continue as a going concern beyond the third quarter of 2026 without additional financing.
• The FDA accepted INOVIO's Biologics License Application (BLA) for INO-3107 for recurrent respiratory papillomatosis (RRP) under the accelerated approval program, but noted a preliminary conclusion that adequate information to justify accelerated approval eligibility was not provided, resulting in a standard 10-month review with a PDUFA target date of October 30, 2026.
• Clinical data for INO-3107 showed 81% of patients experienced a reduction of one or more surgeries at Year 1 post-treatment, increasing to 91% by Year 2, with 50% requiring no surgery during Year 2.
• A competitor, Precigen, received traditional FDA approval for PAPZIMEOS for RRP in August 2025, positioning INO-3107 as a potential second entrant.
• The company is advancing INO-3112 for HPV-related oropharyngeal squamous cell carcinoma (OPSCC) in a planned Phase 3 clinical trial with Coherus BioSciences, with FDA alignment on the trial design.
• U.S. development of VGX-3100 for cervical high-grade squamous intraepithelial lesions (HSIL) was discontinued in 2023, though collaborator ApolloBio Corporation continues a Phase 3 trial in China.
• Positive preclinical data was presented for DNA-Encoded Protein (DPROT) candidates targeting hemophilia A.
• The company successfully raised $49.0 million from equity offerings in 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with caution due to the significant 'going concern' doubt, the FDA's questioning of accelerated approval for the lead candidate, and declining revenue, despite some positive clinical data and cost reductions.

Positives

• Net loss decreased by 21% year-over-year, from $107.3 million in 2024 to $84.9 million in 2025, indicating improved financial performance.
• Research and development expenses decreased by 28% ($21.4 million reduction) in 2025, demonstrating cost control efforts.
• General and administrative expenses decreased by 12% ($4.3 million reduction) in 2025.
• The FDA accepted INO-3107's BLA for RRP for review under the accelerated approval program, with a PDUFA target date of October 30, 2026.
• INO-3107 demonstrated strong clinical benefit in RRP, with 81% of patients experiencing a reduction of one or more surgeries at Year 1 post-treatment, increasing to 91% by Year 2.
• 50% (14/28) of evaluable RRP patients treated with INO-3107 required no surgery during Year 2, an increase from 28% (9/32) in Year 1.
• INO-3107 showed a 78% reduction in mean annual surgeries at Year 2 compared to the pre-treatment period (0.9 vs 4.1).
• INO-3107 has received Orphan Drug Designation and Breakthrough Therapy Designation from the FDA, and Innovative Medicine designation in the U.K.
• The European Medicines Agency's Committee for Advanced Therapies (CAT) certified the quality and non-clinical data for INO-3107.
• A clinical collaboration and supply agreement was established with Coherus BioSciences for INO-3112 in HPV-related OPSCC, with FDA alignment on the planned Phase 3 trial design.
• Phase 1 clinical study results for COVID-19 DNA-encoded Monoclonal Antibodies (DMAbs) showed durable in vivo antibody production through week 72 and functional activity, with no anti-drug antibodies (ADA).
• INO-4201 (Ebola vaccine booster) elicited strong antibody responses comparable to the ERVEBO primary series vaccination in a Phase 1b trial, and the FDA is aligned on using a non-human primate (NHP) challenge study for immunobridging to Phase 2.
• Promising preclinical data for DNA-Encoded Protein (DPROT) candidates targeting hemophilia A were presented.
• The company successfully raised $49.0 million from equity offerings in 2025, providing capital for operations.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern beyond the third quarter of 2026 due to insufficient working capital.
• The FDA noted a preliminary conclusion that the company had not provided adequate information to justify eligibility for the accelerated approval pathway for INO-3107, leading to a standard 10-month review instead of the requested priority 6-month review.
• Competitor PAPZIMEOS received traditional FDA approval for RRP in August 2025, potentially making INO-3107 a second entrant if approved, which could create a competitive disadvantage.
• The U.S. development program for VGX-3100 for cervical HSIL was discontinued in 2023 after statistical significance was not achieved in the biomarker-selected population in a Phase 3 trial.
• Revenue from collaborative arrangements decreased significantly by 70% in 2025 compared to 2024.
• The accumulated deficit reached $1.8 billion as of December 31, 2025, reflecting significant historical losses.
• Cash, cash equivalents, and short-term investments decreased by $35.6 million year-over-year.
• The company relies on third-party manufacturers and single-source suppliers for critical components, posing risks of delays and supply interruptions.
• A small commercial organization and lack of an in-house sales team mean significant investment or third-party arrangements are needed for commercialization, if products are approved.
• The company is currently subject to litigation, including a shareholder class action and a derivative complaint, alleging materially false and misleading statements regarding the INO-3107 BLA submission and review timeline.
• Future equity financings, necessary to fund operations, could result in substantial dilution to existing stockholders.

Risks

• The company does not currently have sufficient working capital to fund planned operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• Substantial additional capital will be needed to develop DNA medicines and proprietary device technology, which may be difficult or costly to obtain.
• The company has incurred significant losses and expects to incur significant net losses in the foreseeable future, and may never become profitable.
• Product candidates are drug-device combination products, requiring additional time and complexity to obtain regulatory approval for both the biologic and the CELLECTRA delivery devices.
• Intense and increasing competition, including the traditional approval of PAPZIMEOS for RRP, may impede the company's ability to develop and commercialize its DNA medicines.
• The company has limited sources of revenue, and its success is dependent on its ability to develop its DNA medicines and proprietary device technology.
• DNA medicines and CELLECTRA delivery devices are novel approaches; negative perception of their efficacy, safety, or tolerability could adversely affect business and regulatory approvals.
• Reliance on contract manufacturers and single-source suppliers for proprietary devices and DNA medicine candidates poses risks of production delays, supply interruptions, and non-compliance with stringent regulations.
• Loss of or inability to secure collaborators or partners, or inadequate resource allocation by partners, could hinder product development and profitability.
• Agreements with government agencies are subject to termination and uncertain future funding, which could negatively impact pipeline development.
• Ongoing and potential future litigation, including shareholder class action and derivative complaints, could harm the business, financial condition, and reputation.
• Collaborations with Chinese companies and reliance on clinical materials manufactured in China expose the company to uncertainties regarding Chinese laws, trade wars, political unrest, or unstable economic conditions.
• It is difficult and costly to generate and protect intellectual property, and the company may be sued for infringing third-party intellectual property rights.
• The company is subject to stringent and evolving U.S. and foreign data privacy and security laws; failure to comply could lead to regulatory actions, litigation, fines, and reputational harm.
• Clinical trials are lengthy, expensive, and have uncertain outcomes; results of earlier studies may not be predictive of future trial results.
• The use of new endpoints or methodologies for treating diseases with little clinical experience may not be considered clinically meaningful by regulatory authorities.
• The company may be unsuccessful in obtaining new Orphan Drug Designations or maintaining the benefits associated with existing ones.
• Even if products receive regulatory approval, ongoing regulatory obligations and review may result in significant additional expense and penalties for non-compliance.
• Potential product liability exposure from the use of proprietary devices and DNA medicine candidates in clinical trials and commercial sales.
• Healthcare reform measures could hinder or prevent the commercial success of products.
• Misconduct or improper activities by employees, principal investigators, and consultants, including non-compliance with regulatory standards and insider trading, pose risks.
• Health epidemics could adversely affect clinical trial operations and supply chains.
• Failure to successfully acquire, develop, and market additional product candidates would impair growth.
• Changes in funding for the FDA and other government agencies could delay product development or commercialization.
• Compromise of information technology systems or data could lead to material adverse consequences.
• Quarterly operating results may fluctuate significantly, impacting stock price.
• Results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions.
• Dependence on key personnel; inability to attract and retain additional qualified personnel.
• Anti-takeover provisions under charter documents and Delaware law could delay or prevent a change of control.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited.
• The increasing use of social media platforms presents new risks and challenges, including potential noncompliance with regulations and reputational harm.

Future Outlook

The company expects to continue incurring substantial operating losses for the foreseeable future due to ongoing research and development, preclinical studies, clinical trials, and regulatory activities. Additional financing will be required to complete development and commercialize INO-3107 and other product candidates. The current cash runway is expected to extend into the fourth quarter of 2026, without giving effect to any further capital raising activities. The company is evaluating potential collaborations as an additional way to fund operations and aims to achieve profitable operations, though positive cash flow is not guaranteed.

Management Comments

• INOVIO continues to believe that INO-3107 fulfills the criteria for accelerated approval, meeting a significant unmet need and providing a meaningful therapeutic benefit over existing treatments.
• We intend to aggressively prosecute the claims in the complaint and defend the counterclaims [in VGXI litigation].
• We intend to defend both actions [securities litigation] vigorously.
• Management believes that there is substantial doubt about our ability to continue as a going concern beyond the third quarter of 2026.

Industry Context

StockSavvy.ai notes that Inovio operates in the highly competitive biotechnology sector, particularly in DNA medicines, which is a novel and evolving field. The FDA's scrutiny of INO-3107's accelerated approval pathway, coupled with the traditional approval of Precigen's PAPZIMEOS for RRP, highlights the significant regulatory and competitive hurdles in bringing novel therapies to market. While Inovio's DNA medicine platform offers potential advantages like T-cell responses, re-dosing capability, and stability, the broader industry is seeing advancements in viral vector-based and lipid nanoparticle delivery systems from major players like AstraZeneca, Merck, and Pfizer. The challenges in securing market acceptance and favorable reimbursement for novel drug-device combination products are also a common theme in the industry, especially when competing with established or traditionally approved treatments.

Comparison to Industry Standards

• INO-3107 for RRP: Compared to Precigen's PAPZIMEOS (gorilla adenoviral vector-based immunotherapy), which received traditional FDA approval in August 2025. PAPZIMEOS requires additional surgery prior to later doses if visible papilloma are present, unlike INO-3107's patient-centric regimen.
• INO-3112 for OPSCC: Combination with durvalumab showed a median overall survival (OS) of more than 29 months, an improvement over historical data for immune-checkpoint blockade therapy alone or in combination with other HPV therapeutic vaccines, and almost three times the historical OS for monotherapy durvalumab in a similar patient population. This contrasts with historical data for durvalumab where objective responses occurred independently of PD-L1 expression.
• DNA-Encoded Monoclonal Antibodies (DMAbs): Demonstrated durability of in vivo antibody production through week 72 and functional activity against SARS-CoV-2 Spike protein, with no anti-drug antibodies (ADA). This is noted as a common challenge in other gene-based delivery platforms, such as adeno-associated virus (AAV) mediated antibody expression.
• Ebola Vaccine Booster (INO-4201): Elicited strong antibody responses comparable to the ERVEBO primary series vaccination. ERVEBO is a conditionally approved preventative vaccine by EMA and FDA, but not approved for repeat dosing or as a booster.

Corporate Governance

Legal Proceedings

• VGXI Litigation: On June 3, 2020, the company filed a complaint against VGXI, Inc. and GeneOne Life Science, Inc. alleging material breach of a supply agreement. VGXI filed counterclaims on July 7, 2020, alleging breach, misappropriation of trade secrets, and unjust enrichment. All discovery is closed, and the parties are awaiting a trial date.
• Securities Litigation (Carlson v. Inovio Pharmaceuticals, Inc., et al.): Filed on February 6, 2026, alleging materially false and misleading statements regarding the submission to the FDA and the FDA's review timeline for the Biologics License Application for INO-3107. The company, CEO Jacqueline Shea, and CFO Peter Kies are named as defendants.
• Shareholder Derivative Complaint (Shin v. Shea, et al.): Filed on March 5, 2026, asserting state and federal claims based on the same alleged misstatements as the shareholder class action. Accuses the board of directors of failing to exercise reasonable and prudent supervision over management, policies, internal controls, and operations. CEO Jacqueline Shea, CFO Peter Kies, and 7 current directors are named as defendants.

Related Party Transactions

• ApolloBio Corporation: The company has an Amended and Restated License and Collaboration Agreement with ApolloBio, granting exclusive rights to develop and commercialize VGX-3100 in China, Hong Kong, Macao, and Taiwan. The company is entitled to receive up to $20.0 million in milestones and tiered royalties (lowto mid-teens) on annual net sales. Revenue from ApolloBio was $65,000 in 2025.
• Plumbline Life Sciences, Inc. (PLS): The company owned 597,808 shares (14.5% ownership interest) in PLS as of December 31, 2025, valued at $2.1 million. Dr. David B. Weiner, a director of the company, acts as a consultant to PLS.
• The Wistar Institute: The company has collaborative research agreements with Wistar. Dr. David B. Weiner, a director of the company, is a director of the Vaccine Center and an Executive Vice President of Wistar. The company recorded $871,000 as contra-research and development expense from Wistar in 2025.
• Geneos Therapeutics, Inc.: The company holds 23% of the outstanding equity of Geneos. Dr. Laurent Humeau (Chief Scientific Officer) is on Geneos' Board, and Dr. David B. Weiner (director) is Chairman of its Scientific Advisory Board. The company licenses its immunotherapy platform and CELLECTRA technology to Geneos.

Stakeholder Impact

• Shareholders: Face potential for substantial dilution from future equity financings, risk of loss of investment due to the 'going concern' doubt, and impact from stock price volatility and ongoing litigation.
• Employees: Competition for qualified personnel is intense, and there is a risk of job eliminations as part of cost-cutting measures. Employee morale and retention could be impacted by financial uncertainty and litigation.
• Customers/Patients: Potential for new treatments for RRP, OPSCC, Ebola, and other diseases if products receive regulatory approval. Delays in regulatory approval could impact patient access to these therapies.
• Suppliers/Creditors: Face risks of supply chain disruptions due to reliance on single-source suppliers and contract manufacturers. The 'going concern' doubt could impact the company's ability to meet its financial obligations to creditors.
• Regulatory Authorities: The company's novel drug-device combination products and pursuit of accelerated approval pathways are subject to increased scrutiny and evolving regulatory requirements.

Next Steps

• Meet with the FDA to discuss maintaining eligibility for accelerated approval for INO-3107.
• FDA review of INO-3107 BLA with a PDUFA target date of October 30, 2026.
• Conduct a planned Phase 3 clinical trial for INO-3112 in HPV-16/-18 positive OPSCC in collaboration with Coherus BioSciences.
• ApolloBio Corporation continues its Phase 3 clinical trial of VGX-3100 in China.
• Continue the ongoing Phase 1b investigator-sponsored trial for INO-5401 in BRCA1/2 mutation patients.
• Perform further pharmacokinetic analyses of clinical samples from the COVID-19 DMAb trial.
• Inform the design of a potential Phase 3 study for INO-4201 (Ebola vaccine booster) based on results from NHP challenge study and Phase 2 clinical study.
• Continue analysis for the Phase 1 trial of INO-6172 (DLNP for HIV).
• Progress additional preclinical work with DLNP technology for other HIV DNA vaccine candidates.
• Identify partnership opportunities for DPROT and DMAb preclinical stage candidates.
• Evaluate INO-5412 in combination with cadonilimab in GBM as part of the INSIGhT Phase 2 adaptive platform trial.
• Seek additional capital through strategic alliances, licensing, grants, debt, or equity financings.
• File the definitive proxy statement with the Commission not later than 120 days after December 31, 2025.

Key Dates

Recommendation

The filing presents significant red flags for investors, primarily the 'substantial doubt' about the company's ability to continue as a going concern beyond Q3 2026. This fundamental liquidity issue, combined with the FDA's questioning of accelerated approval eligibility for the lead candidate INO-3107 and the prior approval of a competitor's RRP drug, creates a highly uncertain and unfavorable outlook. While some positive clinical data is present and cost reductions are noted, these are overshadowed by the severe financial and regulatory challenges, including ongoing litigation and the need for substantial future capital raises that could lead to significant shareholder dilution. A seasoned investor would likely view these risks as outweighing any potential upside in the near to medium term.

Keywords

DNA medicines, electroporation, RRP, INO-3107, HPV, cancer immunotherapy, glioblastoma, Ebola vaccine, biotechnology, clinical-stage, FDA approval, accelerated approval, orphan drug, breakthrough therapy, CELLECTRA, biologics license application, pharmaceuticals, recurrent respiratory papillomatosis, HPV-associated diseases, infectious diseases, oncology, drug-device combination, intellectual property, going concern, capital raise, clinical trials, regulatory risk, product development, commercialization, PAPZIMEOS, VGX-3100, INO-3112, OPSCC, DMAb, DPROT, DLNP